CD133 expression has been demonstrated as a marker of CSC-like populations in many tumors, including laryngeal cancer; therefore, the effect of FOXD2-AS1 on the CD133-positive cell population of LSCC was detected using immunofluorescence. The gene discussed is PROM1; the disease is laryngeal carcinoma.